The Zhitong Finance App learned that Tianfeng Securities released a research report stating that the first payment for Luye Pharmaceutical (02186) has a “buy” rating. The estimated revenue for 2023-2025 is 61.24/69.91/8.529 billion yuan, and net profit to mother is 6.22/8.09/1,373 billion yuan. Considering the company's obvious advantages in the field of central nervous system and oncology, risperidone and toluvenlafaxine have been approved for listing. Potential varieties such as rotigotine, goserelin, and rubitidine are expected to usher in rapid release after marketing. We are optimistic about the company's development. The target price is HK$4.97.
According to the report, the company has launched mature products: many products have been recognized by the medical community to provide the company with stable cash flow. As the only paclitaxel liposome marketed in the world, liposin has fast curative effect and high safety characteristics. Compared with albumin paclitaxel and paclitaxel polymer micelles, it can cover more indications, and its market share continues to increase; Siricom is the original research variety, and sales are expected to remain stable; Xericang is the first domestic natural statine with evidence-based evidence. Exclusive promotion rights were granted to AstraZeneca in 2019. AstraZeneca continues to expand the sales market for blood lipids, and sales are expected to continue to grow.